Bruce Jackson

Eric Pansick

Jason Kolbert

Jason McCarthy

Laura Engel

Laura Engle

Raymond Myers

Scott Billeadeau

- Sonoma Pharmaceuticals, Inc. reported strong financial performance, with revenues increasing **12%** for the fiscal year ended **March 31, 2025**, and **18%** for the three months ended **June 30, 2025**, compared to the same periods in the prior year, driven by a **57% increase in U.S. revenues** in Q1 2026.  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]**  Net loss and EBITDA loss also showed significant improvement.  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]** 
- The company has expanded its market reach and distribution network through key partnerships, including agreements with **Medline Industries, LP** for wound care in the U.S. and Canada (August and October 2024) and **WellSpring Pharmaceutical Corporation** for sales to large U.S. retailers (starting January 2025).  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:3]** **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]**  Sonoma also launched acne products in the UK in **April 2025**.  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]** 
- Sonoma Pharmaceuticals continues to innovate and secure regulatory approvals for its hypochlorous acid (HOCl) products, launching an HOCl-based diaper rash product in **August 2025**, relaunching several prescription and OTC products in **December 2024**, and obtaining **two new 510(k) clearances from the FDA in 2024**.  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:4]** **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]**  The company also successfully transitioned all commercialized products in Europe to the new EU Medical Device Regulation (MDR).  **[1367083_0001683168-25-007307_sonoma_ex9901.htm:5]**

Sonoma Pharmaceuticals (SNOA)